Publications scientifiques

Depuis le 07/11/2022

  1. Transparency and robustness of safety signals.
    Khouri C, Fusaroli M, Salvo F, Raschi E.
    BMJ. 2022
  2. Incidence of Heart Failure following Exposure to a Protein Kinase Inhibitor (PKI), a French Population-based Study.
    Zelmat Y, Conte C, Noize P, Vabre C, Pajiep M, Lafaurie M, Lapeyre-Mestre M, Despas F.
    Br J Clin Pharmacol. 2022
  3. JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study.
    Gouverneur A, Avouac J, Prati C, Cracowski JL, Schaeverbeke T, Pariente A, Truchetet ME.
    Eur J Clin Pharmacol. 2022
  4. Second-degree burn induced by high-concentration topical capsaicin with mobility sequelae: a case report.
    Trin K, Perino J, Allouchery M, Géniaux H, Miremont G, Salvo F.
    Pain Pract. 2022
  5. Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
    Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F; French CML Group (FiLMC).
    Br J Haematol. 2022
  6. Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study.
    Mathieu C, Pambrun E, Bénard-Laribière A, Noize P, Faillie JL, Bezin J, Pariente A.
    Eur J Epidemiol. 2022
  7. Benefit-risk balance of COVID drugs. New prospects.
    Cracowski JL, Richard V, Molimard M.
    Therapie. 2022
  8. A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.
    Guyon J, Novion M, Fulda V, Ducint D, Molimard M, Couzi L, Kaminski H, Salvo F, Bouchet S.
    J Am Soc Mass Spectrom. 2022
  9. Minors and young adult's hospitalizations after "chimique" consumption in Mayotte Island: Which substances are involved?
    Goncalves R, Peyré A, Castaing N, Beeken T, Olivier S, Combe P, Miremont-Salamé G, Titier K, Molimard M, Daveluy A.
    Therapie. 2022
  10. Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
    Johnson-Ansah H, Maneglier B, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, Cony-Makhoul P, Coiteux V, Sutton L, Abarah W, Pouaty C, Pignon JM, Choufi B, Visanica S, Deau B, Morisset L, Cayssials E, Molimard M, Bouchet S, Mahon FX, Nicolini F, Aegerter P, Cayuela JM, Delord M, Bruzzoni-Giovanelli H, Rousselot P; Groupe Français pour la LMC (Fi-LMC).
    Pharmaceutics. 2022
  11. Urine biomonitoring of occupational exposure to methotrexate using a highly sensitive UHPLC-MS/MS method in MRM3 mode.
    Villa A, Tremolet K, Martinez B, Petit M, Dascon X, Stanek J, Ducint D, Titier-Debeaupuis K, Verdun-Esquer C, Molimard M, Canal-Raffin M.
    J Chromatogr B Analyt Technol Biomed Life Sci. 2022
  12. [Hospitalizations after substance use during the COVID-19 pandemic]
    Dumoulin C, Ong N, Ramaroson H, Létinier L, Miremont-Salamé G, Gilleron V, Daveluy A, Perino J.
    Therapie. 2022
  13. Neuromodulation Treatments of Pathological Anxiety in Anxiety Disorders, Stressor-Related Disorders, and Major Depressive Disorder: A Dimensional Systematic Review and Meta-Analysis.
    Florian G, Singier A, Aouizerate B, Salvo F, Bienvenu TCM.
    Front Psychiatry. 2022
  14. Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use.
    Bertin C, Bezin J, Chenaf C, Delorme J, Kerckhove N, Pariente A, Tournier M, Authier N.
    Front Psychiatry. 2022
  15. Potentially inappropriate medication use by level of polypharmacy among US Veterans 49-64 and 65-70 years old.
    Guillot J, Rentsch CT, Gordon KS, Justice AC, Bezin J.
    Pharmacoepidemiol Drug Saf. 2022
  16. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
    Rosellini P, Amintas S, Caumont C, Veillon R, Galland-Girodet S, Cuguillière A, Nguyen L, Domblides C, Gouverneur A, Merlio JP, Bezin J, Girodet PO.
    Eur J Cancer. 2022
  17. Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry.
    Spini A, Rosellini P, Bellan C, Furiesi F, Giorgi S, Donnini S, Gini R, Ziche M, Salvo F, Roberto G.
    PLoS One. 2022
  18. Myocardial infarction associated with erenumab: a case report.
    Perino J, Corand V, Laurent E, Théophile H, Miremont-Salamé G, Pariente A, Colas JL, Couffinhal T, Salvo F.
    Pharmacotherapy. 2022
  19. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).
    Lemaitre F, Grégoire M, Monchaud C, Bouchet S, Saint-Salvi B, Polard E; SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT); French Pharmacovigilance Network (CRPV); ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group; SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT); French Pharmacovigilance Network (CRPV); ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group.
    Therapie. 2022
  20. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics.
    Humbert M, Bourdin A, Taillé C, Kamar D, Thonnelier C, Lajoinie A, Rigault A, Deschildre A, Molimard M.
    Eur Respir J. 2022